Vorapaxar

Administration

  • Type: Antiplatelet
  • Dosage Forms: Tab 2.08mg
  • Routes of Administration: Oral
  • Common Trade Names: Zontivity

Adult Dosing

Thrombotic event prevention

  • 2.08 mg PO qd

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

  • Caution advised during pregnancy
  • Risk of increased maternal bleeding during delivery

Lactation risk

  • Consider alternative while breastfeeding
  • Possible drug excretion into milk based on drug properties

Renal Dosing

  • Adult: No adjustment
  • Pediatric: Unavailable

Hepatic Dosing

  • Adult:
    • Severe Impairment: Avoid use
  • Pediatric: Unavailable

Contraindications

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 8 days w/ active metabolite
  • Metabolism: Liver CYP450: 2J2, 3A4 substrate
  • Excretion: Feces 58%, urine 25%

Mechanism of Action

  • Antagonizes protease-activated receptor-1, inhibiting platelet aggregation induced by thrombin an thrombin receptor agonist peptide

Comments

See Also

References

Authors:

Jonathan Warren